FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to dermatology, and can be used for selecting a therapeutic approach to acne in females by examining biological fluids and prescribing preparations depending on the clinical findings. The biological fluids are blood and urine; blood serum hormones and steroid urine profile are tested, and the derived values are compared to the standard norms specific for the absence of acne, while the preparations are prescribed according to the comparison results. Specifically, if observing an increase of blood luteinising hormone up to 16 mIU/ml, testosterone up to 4 ng/ml, an increase of urine androsterone up to 20 mcmole/24 hours, etiocholanolone up to 11 mcmole/24 hours, total 17-ketosteroids up to 35 mcmole/24 hours, van de Calseyde's discriminant up to 3, the combined oral contraceptive Jess with the anti-androgenic effect. If also observing an increase of immunoreactive protein up to 12.90 mcUnit/ml and insulin-line growth factor 1 up to 361.04 ng/ml, the combined oral contraceptive Jess and Metformine or Metformine are prescribed. If observing a decrease of blood oestradiol up to 140 pmole/l or an increase of the concentration of luteinising hormone up to 7 mIU/ml, dihydroepiandrosterone sulphate up to 4 mmole/l, 17 - hydroxyprogesterone up to 4 nmole/l and testosterone up to 4 nmole/l in blood and an increase of urine androsterone up to 17 mcmole/24 hours, etiocholanolone up to 17 mcmole/24 hours, 11 - ketoandrosterone up to 2.5 mcmole/24 hours, 11 - ketoetiocholanolone up to 2.5 mcmole/24 hours, 17 - ketosteroids up to 50 mcmole/24 hours and van de Calseyde's discriminant up to 3, the glucocorticoid Metypred is prescribed. The high blood concentration of luteinising hormone up to 15 mIU/ml, dihydroepiandrosterone sulphate up to 6.82 mcmole/l, 17 - hydroxyprogesterone up to 4 nmole/l and an increase of urine androsterone up to 19.5 mcmole/24 hours, etiocholanolone up to 16 mcmole/24 hours, dihydroepiandrosterone up to 7 mcmole/24 hours, 17 - ketosteroids up to 45 mcmole/24 hours and van de Calseyde's discriminant up to 3.5 enables using the combined oral contraceptive Jess and the glucocorticoid Metypred. And the preparation Dostinex is prescribed in observing the above values in a combination with an increase of blood prolactin up to 750 IU/ml and a decrease of blood oestradiol up to 95.48 pcg/ml.
EFFECT: method enables providing higher therapeutic selectivity and clinical effectiveness in acne without the need of thorough examination to be conducted.
4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATMENT OF TESTICULAR INSUFFICIENCY OF MEN OF REPRODUCING AGE IN CASE OF HYPERESTROGENIA | 0 |
|
SU1398870A1 |
METHOD FOR DIAGNOSING ORGANIC LESIONS OF THE CHIASMAL-SELLAR REGION IN PATIENTS WITH CENTRAL HYPOGONADISM | 2021 |
|
RU2777475C1 |
DIAGNOSTIC TECHNIQUE FOR FOETAL MATURITY | 2009 |
|
RU2399058C1 |
METHOD FOR INTEGRATED TREATMENT OF PATHOZOOSPERMIA IN MALES SUFFERING ADRENAL HYPERANDROGENISM | 2012 |
|
RU2510284C1 |
METHOD FOR PREDICTING HOLLOW FOLLICLES SYNDROME | 2005 |
|
RU2302639C1 |
DIAGNOSTIC TECHNIQUE FOR ADOLESCENT'S REPRODUCTIVE DISORDERS ACCOMPANYING CHRONIC RENAL PATHOLOGY | 2013 |
|
RU2536288C1 |
METHOD FOR CORRECTING LOWERED ANDROGEN OUTPUT SECRETED BY ADRENAL GLAND | 1998 |
|
RU2141261C1 |
METHOD OF CORRECTING HORMONAL STATE DURING POSTCASTRATION SYNDROM IN PATIENTS OF REPRODUCTIVE AGE WITH CERVICAL CANCER | 2016 |
|
RU2619341C1 |
METHOD FOR STEROID PROFILING IN DOPE TEST OF SPORTSMEN | 2011 |
|
RU2467331C1 |
METHOD OF TREATING PATIENTS SUFFERING FROM CHRONIC PROSTATITIS WITH PARTIAL ANDROGEN DEFICIENCY | 2013 |
|
RU2525182C1 |
Authors
Dates
2014-09-27—Published
2012-12-18—Filed